Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIC: Telomerase Activator to Reverse Immunosenescence in Acute Coronary Syndrome
2017-002876-26Phase 2Unknown
- Sponsor
- South Tees Hospitals NHS Foundation Trust
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute coronary syndrome (ACS), immunosenescence and immunocompromise comparing TA-65MD with Placebo (2 arms). Primary endpoint: Immunosenescence measured by CD8+ TEMRA cells. Status: unknown.
02
Drugs
TA-65MD
03
Conditions
acute coronary syndrome (ACS)immunosenescenceimmunocompromise
Beyond the preview
Go deeper on 2017-002876-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002876-26.